[Male urogenital tract mycoplasma infection and drug-resistance evolution].
OBJECTIVE
To investigate the male urogenital tract mycoplasma infection and drug-resistance evolution in 2001 and 2003.


METHODS
The results of mycoplasma culture and drug sensitivity tests were explored in 2001 and 2003, and the differences of drug sensitivity between the two years were analysed.


RESULTS
Of the 109 mycoplasma positive cases in 2001, 86.2% were infected with Ureaplasma urealyticum (Uu), 3.8% with Mycoplasma hominis (Mh), 10.1% with both Uu and Mh; and of the 134 mycoplasma positive cases in 2003, Uu infection accounted for 79.1%, Mh infection 4.48% and Uu and Mh infection 16.4%. Compared with 2001, the drug-resistance rates to roxithromycin, azithromycin, levofloxacin, ofloxacin and clindamycin rose obviously in 2003; but the drug-resistance rates to josamycin, minomycin and doxycycline did not change significantly. As far as the drug sensitivity rate is concerned, josamycin ranked the first, and doxycycline the second.


CONCLUSIONS
Mycoplasma was a high rate of drug-resistance, and the drug sensitivity evolves with the time. Treatment for mycoplasma should be based on the results of drug sensitivity tests. Josamycin can be used as the first choice.
Guo
Xiaolin
X
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Ye
Zhangqun
Z
Deng
Rongjin
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D024881:Drug Resistance, Bacterial; D005832:Genital Diseases, Male / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009175:Mycoplasma Infections / Q000188:drug therapy*